Claritin Appeals Court Endorses Metabolite Patents, But Not Broad Claims
Executive Summary
Metabolites of known drugs may not receive patent protection through broad compound claims, a D.C. federal appeals court ruled Aug. 1 in the Claritin patent infringement case
You may also be interested in...
PTO Tougher On Patent Claims Following Claritin Metabolite Ruling – Attorney
Patenting drug claims has become more difficult due to recent court rulings in Waxman/Hatch cases, attorney Anthony Insogna said during a panel discussion at the J.P. Morgan health care conference in San Francisco Jan. 14
PTO Tougher On Patent Claims Following Claritin Metabolite Ruling – Attorney
Patenting drug claims has become more difficult due to recent court rulings in Waxman/Hatch cases, attorney Anthony Insogna said during a panel discussion at the J.P. Morgan health care conference in San Francisco Jan. 14
Claritin Metabolite Ruling Will Impact Biologics, Dissenting Judges Say
A federal appeals court's decision in Schering-Plough's Claritin patent infringement case could hold serious implications for future new drugs and biologics, two dissenting judges said